These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26564024)

  • 1. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.
    Pun PH; Abdalla S; Block GA; Chertow GM; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Goodman WG; Herzog CA; London GM; Mahaffey KW; Moe SM; Parfrey PS; Wheeler DC; Middleton JP
    Hemodial Int; 2016 Jul; 20(3):421-31. PubMed ID: 26564024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Moe SM; Chertow GM; Parfrey PS; Kubo Y; Block GA; Correa-Rotter R; Drüeke TB; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Stolina M; Dehmel B; Goodman WG; Floege J;
    Circulation; 2015 Jul; 132(1):27-39. PubMed ID: 26059012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
    Chang TI; Abdalla S; London GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; Mahaffey KW; Moe SM; Parfrey PS; Wheeler DC; Dehmel B; Goodman WG; Chertow GM
    J Hum Hypertens; 2016 Mar; 30(3):204-9. PubMed ID: 26040438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
    Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
    J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.
    Pasch A; Block GA; Bachtler M; Smith ER; Jahnen-Dechent W; Arampatzis S; Chertow GM; Parfrey P; Ma X; Floege J
    Clin J Am Soc Nephrol; 2017 Feb; 12(2):315-322. PubMed ID: 27940458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients.
    Jean G; Souberbielle JC; Zaoui E; Lorriaux C; Hurot JM; Mayor B; Deleaval P; Mehdi M; Chazot C
    BMC Nephrol; 2016 Oct; 17(1):153. PubMed ID: 27756251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients.
    Pun PH; Horton JR; Middleton JP
    Clin J Am Soc Nephrol; 2013 May; 8(5):797-803. PubMed ID: 23371957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
    Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
    Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.
    Abdalla S; Montez-Rath ME; Parfrey PS; Chertow GM
    Contemp Clin Trials; 2016 May; 48():119-24. PubMed ID: 27080930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
    Chertow GM; Pupim LB; Block GA; Correa-Rotter R; Drueke TB; Floege J; Goodman WG; London GM; Mahaffey KW; Moe SM; Wheeler DC; Albizem M; Olson K; Klassen P; Parfrey P
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):898-905. PubMed ID: 17702710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet and Clinical Outcomes in Dialysis.
    Komaba H; Fukagawa M
    Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation.
    Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
    Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
    Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
    Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of cinacalcet on vascular calcification].
    Yokoyama K
    Clin Calcium; 2015 May; 25(5):729-36. PubMed ID: 25926577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethylamine
    Stubbs JR; Stedman MR; Liu S; Long J; Franchetti Y; West RE; Prokopienko AJ; Mahnken JD; Chertow GM; Nolin TD
    Clin J Am Soc Nephrol; 2019 Feb; 14(2):261-267. PubMed ID: 30665924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.
    Briggs AH; Parfrey PS; Khan N; Tseng S; Dehmel B; Kubo Y; Chertow GM; Belozeroff V
    Med Decis Making; 2016 Nov; 36(8):965-72. PubMed ID: 26987347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.